

Medical drug benefit *Clinical Criteria* updates

On August 21, 2020, the Pharmacy and Therapeutics (P&T) Committee approved the following *Clinical Criteria* applicable to the **medical drug benefit** for Anthem Blue Cross. These policies were developed, revised or reviewed to support clinical coding edits.

Visit [Clinical Criteria](#) to search for specific policies. If you have questions or would like additional information, use this [email](#).

Please see the explanation/definition for each category of *Clinical Criteria* below:

- New: newly published criteria
- Revised: addition or removal of medical necessity requirements, new document number
- Annual review: minor wording and formatting updates, new document number
- Updates marked with an asterisk (*): criteria may be perceived as more restrictive

Please share this notice with other members of your practice and office staff.

Please note: The *Clinical Criteria* listed below applies only to the medical drug benefits contained within the member’s medical plan. This does not apply to pharmacy services.

Effective date	Document number	<i>Clinical Criteria</i> title	New, revised, annual review
1/8/2021	ING-CC-0170*	Uplizna (inebilizumab)	New
1/8/2021	ING-CC-0172*	Viltepsa (viltolarsen)	New
1/8/2021	ING-CC-0173*	Enspryng (satralizumab-mwge)	New
1/8/2021	ING-CC-0174*	Kesimpta (ofatumumab)	New
1/8/2021	ING-CC-0168*	Tecartus (brexucabtagene autoleucel)	New
1/8/2021	ING-CC-0171*	Zepzelca (lurbinectedin)	New
1/8/2021	ING-CC-0169*	Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)	New
1/8/2021	ING-CC-0175*	Proleukin (aldesleukin)	New
1/8/2021	ING-CC-0176*	Beleodaq (belinostat)	New
1/8/2021	ING-CC-0178*	Synribo (omacetaxine mepesuccinate)	New
1/8/2021	ING-CC-0177*	Zilretta (triamcinolone acetonide extended-release)	New
1/8/2021	ING-CC-0166*	Trastuzumab Agents Step Therapy	New
1/8/2021	ING-CC-0167*	Rituximab Agents for Oncologic Indications Step Therapy	New
1/8/2021	ING-CC-0058*	Octreotide Agents (Byngezia Pen, Sandostatin or Sandostatin LAR)	Revised
1/8/2021	ING-CC-0015*	Infertility and HCG Agents	Revised
1/8/2021	ING-CC-0077*	Palynziq (pegvaliase-pqpz)	Revised

<https://mediproviders.anthem.com/ca>

Anthem Blue Cross Cal MediConnect Plan is a health plan that contracts with both Medicare and Medi-Cal to provide benefits of both programs to enrollees. Anthem Blue Cross is the trade name of Blue Cross of California. Anthem Blue Cross and Blue Cross of California Partnership Plan, Inc. are independent licensees of the Blue Cross Association. ANTHEM is a registered trademark of Anthem Insurance Companies, Inc.

Effective date	Document number	<i>Clinical Criteria</i> title	New, revised, annual review
1/8/2021	ING-CC-0042	Monoclonal Antibodies to Interleukin-17	Revised
1/8/2021	ING-CC-0064	Interleukin-1 Inhibitors	Revised
1/8/2021	ING-CC-0050	Monoclonal Antibodies to Interleukin-23	Revised
1/8/2021	ING-CC-0082*	Onpattro (patisiran)	Revised
1/8/2021	ING-CC-0084*	Tegsedi (inotersen)	Revised
1/8/2021	ING-CC-0010*	Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Inhibitors	Revised
1/8/2021	ING-CC-0027*	Denosumab Agents	Reviewed
1/8/2021	ING-CC-0019*	Zoledronic Acid Agents	Reviewed
1/8/2021	ING-CC-0002*	Colony Stimulating Factor Agents	Revised
1/8/2021	ING-CC-0001*	Erythropoiesis Stimulating Agents	Revised
1/8/2021	ING-CC-0132	Mylotarg (gemtuzumab ozogamicin)	Revised
1/8/2021	ING-CC-0124	Keytruda (pembrolizumab)	Revised
1/8/2021	ING-CC-0125*	Opdivo (nivolumab)	Revised
1/8/2021	ING-CC-0119*	Yervoy (ipilimumab)	Revised
1/8/2021	ING-CC-0129	Bavencio (avelumab)	Revised
1/8/2021	ING-CC-0104	Levoleucovorin Agents	Revised
1/8/2021	ING-CC-0094*	Alimta (pemetrexed disodium)	Revised
1/8/2021	ING-CC-0061*	GnRH Analogs for the Treatment of Nononcologic Indications	Revised
1/8/2021	ING-CC-0009*	Lemtrada (alemtuzumab) for the Treatment of Multiple Sclerosis	Revised
1/8/2021	ING-CC-0029	Dupixent (dupilumab)	Revised
1/8/2021	ING-CC-0038*	Human Parathyroid Hormone Agents	Revised
1/8/2021	ING-CC-0139	Evenity (romosozumab-aqqg)	Revised
1/8/2021	ING-CC-0044*	Exondys 51 (eteplirsen)	Revised
1/8/2021	ING-CC-0152*	Vyondys 53 (golodirsen)	Revised
1/8/2021	ING-CC-0035*	Duopa (carbidopa and levodopa enteral suspension)	Revised
1/8/2021	ING-CC-0048*	Spinraza (nusinersen)	Revised